Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsGold Coast Health Plan Alyglo Prior Auth | OpenPay…
    Ask Trek AI about this page
    CurrentGold Coast Health PlanPolicy N/A

    Alyglo (immune globulin intravenous, human-stwk) Coverage Criteria

    Customize your policy alerts

    Sign up for all goldcoasthealthplan policy alerts

    Know when goldcoasthealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medicare Part B prior authorization and coverage criteria for Alyglo in adults with primary humoral immunodeficiency, including documentation, dosing, coverage duration, and HCPCS billing requirements.

    Policy Summary
    PayerGold Coast Health Plan
    PolicyAlyglo (immune globulin intravenous, human-stwk) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 21, 2025
    Last ReviewAug 21, 2025
    Next Review DateN/A
    Key ActionSubmit medical records documenting prior therapies and responses, and ensure the request follows LCD L34771 for Immune Globulins.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    J1552HCPCS code
    500 mgBilling unit
    2 yearsCoverage duration
    AdultsCovered population

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    5 g–20 g
    Vial presentations

    Alyglo Coverage Criteria

    Alyglo Initial Coverage

    Alyglo is covered when ALL of the following requirements are met:

    ALL of the following

    • The requested drug is Alyglo (immune globulin intravenous, human-stwk) for the treatment of primary humoral immunodeficiency (PI) in an adult, including but not limited to congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, or severe combined immunodeficiency.
    • Medical records supporting the request are submitted, including documentation of prior therapies and responses to treatment.
    • The request follows CMS Local Coverage Determination (LCD) L34771 for Immune Globulins: https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=34771&ver=49&

      The Gold Coast Health Plan Medicare Part B Reference and Summary of Evidence document also applies.

    • The requested dose is consistent with FDA-approved labeling or accepted standards of medical practice.

      Dose approval is subject to the FDA-approved labeling or accepted standards of medical practice.

    • No age restriction applies.
    • No prescriber restriction applies.
    • No exclusion criteria apply.
    • The requested coverage period is no more than two years.<= 2 years

      Refer to the Gold Coast Health Plan Medicare Part B Reference and Summary of Evidence document for additional information.

    • When billed under HCPCS J1552, Alyglo is billed per 500 mg unit; available packaging includes 5 g/50 mL, 10 g/100 mL, and 20 g/200 mL single-dose vials.

      HCPCS J1552: Alyglo (immune globulin intravenous, human-stwk). Billing unit: 500 mg.

    HCPCS Coding and Billing

    Covered HCPCS CodesHCPCSCovered
    J1552Alyglo (immune globulin intravenous, human-stwk); billing unit: 500 mg; supplied as 5 g/50 mL, 10 g/100 mL, or 20 g/200 mL single-dose vial (SDV)

    Prior Authorization and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for Alyglo (J1552) when used to treat primary humoral immunodeficiency (PI) in adults. Submit the medical record documentation required to support the request.

    • Covered indication includes, but is not limited to, congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.
    • Dose is approved according to FDA-approved labeling or accepted standards of medical practice; coverage duration is two years.
    Documentation Required

    Required Medical Records

    Medical records supporting the Alyglo request must be submitted with documentation of prior therapies and the patient's responses to treatment.

    • Document the prior treatments attempted.
    • Include the clinical response to each prior therapy, including lack of response or treatment failure when applicable.

    Alyglo Background

    Alyglo is an intravenous immune globulin indicated for adults with primary humoral immunodeficiency. Covered conditions include congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiencies. Coverage requires supporting medical records and adherence to LCD L34771 for Immune Globulins.

    Relevant Definitions

    Primary humoral immunodeficiency (PI)
    DefinitionPrimary humoral immunodeficiency (PI) is the covered indication for Alyglo in adults.
    ExamplesCongenital agammaglobulinemia and common variable immunodeficiency (CVID).
    Additional examplesWiskott-Aldrich syndrome and severe combined immunodeficiencies.
    Common variable immunodeficiency (CVID)
    AbbreviationCVID
    Full nameCommon variable immunodeficiency.
    Policy contextCVID is listed as an example of primary humoral immunodeficiency covered for Alyglo treatment in adults.

    Initial Alyglo Therapy

    Initial Alyglo Therapy

    Alyglo is covered for initial therapy when ALL of the following are met:

    Initial therapy criteria

    • Covered indication: The patient is an adult with primary humoral immunodeficiency.Adult

      Covered examples include congenital agammaglobulinemia, common variable immunodeficiency (CVID), Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.

    • Required documentation: Medical records supporting the request must be submitted, including documentation of prior therapies and responses to treatment.
    • LCD requirement: The request must follow LCD L34771 for Immune Globulins.

    Coverage Duration and Dosing

    Coverage Duration and Dosing

    Coverage may be approved for two years. ALL of the following apply:

    Coverage duration and dosing

    • Approval duration: Alyglo may be approved for a coverage duration of two years.Two years
    • Dose: The dose must be consistent with FDA-approved labeling or within accepted standards of medical practice.

      Refer to the Gold Coast Health Plan Medicare Part B Reference and Summary of Evidence document.

    Dose and Billing Unit

    Alyglo
    Dosing requirementDose is approved according to FDA-approved labeling or within accepted standards of medical practice.
    Billing unit500 mg per billing unit.
    Coverage durationTwo years.
    Policy Summary
    PayerGold Coast Health Plan
    PolicyAlyglo (immune globulin intravenous, human-stwk) Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateAug 21, 2025
    Last ReviewAug 21, 2025
    Next Review DateN/A
    Key ActionSubmit medical records documenting prior therapies and responses, and ensure the request follows LCD L34771 for Immune Globulins.
    SourceLink
    On This Page
    Alyglo Coverage CriteriaHCPCS Coding and BillingPrior Authorization and DocumentationAlyglo BackgroundRelevant DefinitionsInitial Alyglo TherapyCoverage Duration and DosingDose and Billing Unit
    Denial Risk

    Denial Risk: Insufficient Documentation or LCD Noncompliance

    Requests may be denied when supporting documentation is insufficient or when the request does not follow LCD L34771 for Immune Globulins.

    • Provide complete medical records supporting the diagnosis, indication, prior therapies, and treatment responses.
    • Follow CMS LCD L34771 for Immune Globulins: https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=34771&ver=49&=
    LCD L34771